Cardiovascular disease (CVD) is responsible for more
|
|
- Lambert Rose
- 5 years ago
- Views:
Transcription
1 Epidemiology and Prevention Impact of Blood Pressure and Blood Pressure Change During Middle Age on the Remaining Lifetime Risk for Cardiovascular Disease The Cardiovascular Lifetime Risk Pooling Project Norrina Allen, PhD; Jarett D. Berry, MD, MS; Hongyan Ning, MD, MS; Linda Van Horn, PhD, RD; Alan Dyer, PhD; Donald M. Lloyd-Jones, MD, ScM Background Prior estimates of lifetime risk (LTR) for cardiovascular disease (CVD) examined the impact of blood (BP) at the index age and did not account for changes in BP over time. We examined how changes in BP during middle age affect LTR for CVD, coronary heart disease, and stroke. Methods and Results Data from 7 diverse US cohort studies were pooled. Remaining LTRs for CVD, coronary heart disease, and stroke were estimated for white and black men and women with death free of CVD as a competing event. LTRs for CVD by BP strata and by changes in BP over an average of 14 years were estimated. Starting at 55 years of age, we followed up men and women for person-years. LTR for CVD was 52.5% (95% confidence interval, ) for men and 39.9% (95% confidence interval, ) for women. LTR for CVD was higher for blacks and increased with increasing BP at index age. Individuals who maintained or decreased their BP to normal levels had the lowest remaining LTR for CVD, 22% to 41%, compared with individuals who had or developed by 55 years of age, 42% to 69%, suggesting a dose-response effect for the length of time at high BP levels. Conclusions Individuals who experience increases or decreases in BP in middle age have associated higher and lower remaining LTR for CVD. Prevention efforts should continue to emphasize the importance of lowering BP and avoiding or delaying the incidence of to reduce the LTR for CVD. (Circulation. 2012;125:37-44.) Key Words: cardiovascular diseases coronary disease risk factors stroke Cardiovascular disease (CVD) is responsible for more than one third of all deaths in the United States. 1 Although CVD mortality rates have decreased over the past 4 decades, it remains the leading cause of death and one of the top causes of functional disability. 1 Given the burden of CVD, further efforts are needed to improve CVD prevention. Clinical practice guidelines focused on prevention have recommended developing lifetime risk (LTR) estimates as a method for improved long-term prediction for individuals, better estimation of the burden in the population, and more appropriate comparisons of risk between diseases. 2,3 In addition, LTR estimates appear to be particularly useful in education campaigns because they may be more easily understood than traditional epidemiological measures. 3,4 Clinical Perspective on p 44 The LTR for CVD among whites has been estimated to be 1 in 2 for men and 1 in 3 for women. 5 Data from a single cohort with a limited number of blacks suggest that black men and women have LTRs for CVD death at least as high as those for whites of the same sex. 6 In addition, the LTR for CVD increases with increasing risk factor burden. 6,7 Blood (BP) represents one of the most important modifiable risk factors for CVD. The LTR for CVD, particularly stroke, increases dramatically with increasing BP for both blacks and whites such that the remaining LTR for CVD was twice as high among individuals with stage 2 in middle age compared with those with optimal BP levels. 7 Previous studies of the LTR for CVD have been limited to single measures of BP during middle age. 8 However, to be more useful for individualized risk prediction and communication, detailed, risk factor specific LTR estimates must be developed. 4 Systolic BP generally increases linearly with age, and individuals with higher systolic BP experience the largest increases. 9 However, little is known about how changes in BP Received October 15, 2010; accepted November 11, From the Department of Preventive Medicine (N.A., H.N., L.V.H., A.D., D.M.L.-J.) and Bluhm Cardiovascular Institute, Department of Medicine (D.M.L.-J.), Northwestern University Feinberg School of Medicine, Chicago, IL, and UT Southwestern Medical Center, Department of Medicine, Division of Cardiology, Dallas, TX (J.D.B.). The online-only Data Supplement is available with this article at /-/DC1. Correspondence to Donald M. Lloyd-Jones, MD, ScM, Department of Preventive Medicine and Division of Cardiology, Feinberg School of Medicine, Northwestern University, 680 N Lake Shore Dr, Ste 1102, Chicago, IL dlj@northwestern.edu 2011 American Heart Association, Inc. Circulation is available at DOI: /CIRCULATIONAHA
2 38 Circulation January 3/10, 2012 during middle age may affect the LTR for CVD. Accordingly, we examined the impact of BP at specific ages and BP change over 10 years on the LTR for all CVD and for fatal and nonfatal coronary heart disease (CHD) and stroke among black and white men and women in the Lifetime Risk Pooling Project. Methods Study Sample Data for this study came from the Cardiovascular Lifetime Risk Pooling Project. Detailed methods for the Pooling Project have previously been published. 7 In brief, data from 17 US epidemiological cohort studies were pooled to create the Cardiovascular Lifetime Risk Pooling Project. All cohorts had to meet several criteria: (1) community- or population-based sampling or large volunteer cohort; (2) availability of at least 1 baseline examination at which participants provided demographic, personal, and medical history information and underwent direct measurement of physiological or anthropometric variables (eg, BP, weight); (3) longitudinal follow-up of at least 10 years with complete or near-complete ascertainment of vital status; and (4) availability of cause-specific or cardiovascular mortality data with or without ascertainment of nonfatal cardiovascular events. Because one of the chief aims of the Cardiovascular Lifetime Risk Pooling Project is to compare LTRs between different race/ethnic groups, we specifically sought to obtain data from cohort studies that included nonwhite race/ethnic groups. We did not include cohorts of individuals that participated in clinical trials, had only self-report of risk factors for important covariates without direct physical examination by study investigators, or had few deaths or events. Data sets that included all cardiovascular outcomes, including fatal and nonfatal stroke, were included in this study. These cohorts include the Atherosclerosis Risk in Communities (ARIC) Study, Framingham Heart Study (FHS), Framingham Offspring Study (FOS), Honolulu Heart Program (HHP), Kaiser Permanente Study of the Oldest Old, Cardiovascular Health Study (CHS), and Women s Health Initiative (WHI) Observational Study. Limited-access data sets were obtained from the National Heart, Lung, and Blood Institute (NHLBI) for the ARIC Study, 10 FHS, 11 FOS, 12 and HHP. 13,14 Data from the Kaiser Permanente Study of the Oldest Old 15 were obtained from the Inter-University Consortium for Political and Social Research at the University of Michigan ( Complete data sets were obtained directly by agreement from the CHS 16 and WHI Observational Study 17 investigators. After all of the data were obtained, variables of interest from each data set were cleaned and renamed with the use of a standardized protocol to allow ease of use in the pooling project analyses. Given that data were obtained from cohort studies spanning 6 decades from the 1940s to the 2000s, there were differences between studies in measurement techniques. Whenever possible, values obtained with the most similar techniques were used for analyses. All data were appropriately deidentified, and all study protocols and procedures were approved by the IRB at Northwestern University. BP Measures For all cohorts except the Kaiser Permanente Study, BP was recorded as the average of 2 or 3 seated measurements taken by trained study personnel on manual mercury sphygmomanometers (Table I in the online-only Data Supplement). BP data for participants of the Kaiser Permanente Study of the Oldest Old were taken from clinical measurements recorded in the participants medical record. Participants were grouped according to their index BP as measured within 5 years of each index age. For example, BPs measured in individuals between 40 and 50 years of age were included in the analyses for the index age of 45 years. According to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 18 criteria, the average of at least 2 BP measurements was categorized as follows: normal, 120/ 80 mm Hg untreated; pre, systolic BP of 120 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg untreated with medication; stage 1, systolic BP of 140 to 159 mm Hg or diastolic BP of 90 to 99 mm Hg untreated with medication; and stage 2 or treated, systolic BP 160 mm Hg, diastolic BP 100 mm Hg, or treated with antihypertensive medication. The prevalence of treatment in this study is low because of the time period during which these cohorts were initiated. In addition, although the risk for CVD is reduced for hypertensive individuals who receive antihypertensive medication, their risk remains higher than that for individuals with untreated, ideal BP levels. 19 Therefore, to be conservative, we included treated individuals in the highest-risk group. BP changes were examined among individuals who had at least 2 separate BP measurements 10 years apart. The baseline BP measurement had to have been after 20 years of age and at least 10 years before the BP measurement at the index age, as defined above. On average, baseline BP measurements were recorded 14 years before the index age; ie, on average, baseline BPs were taken at 41 years of age for the index age of 55 years. To classify an individual s change in BP, we collapsed BP into 3 categories: normal, 120/ 80 mm Hg untreated; pre, untreated systolic BP of 120 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg; or, systolic BP 140 mm Hg, diastolic BP 90 mm Hg, or treated. BP change was categorized into 9 categories based on the change from the first to second measurement. Event Ascertainment and Definition For all cohorts except the Kaiser Permanente Study of the Oldest Old, CVD was defined as fatal CHD, hospitalized myocardial infarction, nonhospitalized myocardial infarction, and fatal and nonfatal stroke by trained physician-adjudicators using all available medical records. For death events, many cohorts used linkage to the National Death Index for underlying cause of death from death certificate data, whereas others used adjudicated cause of death by study investigators after review of all available medical records and/or autopsy data. For the present analyses, deaths resulting from CVD (as adjudicated or indicated by International Classification of Disease, 8th revision [ICD-8], ICD-9 codes , and ICD-10 codes I00-I99) or CHD (as adjudicated or indicated by ICD-8 and ICD-9 codes and ICD-10 codes I20-I25) were included. Nonfatal events of interest, including myocardial infarction and stroke, were obtained only from studies that adjudicated events with 1 exception (the Kaiser Permanente Study). Criteria for adjudication of myocardial infarction and stroke have been published for these cohorts: ARIC, 10 CHS, 16 FHS and FOS, 5,8 HHP, 20 and WHI. 17 Diagnosis of myocardial infarction generally required at least two of the following criteria for diagnosis: typical chest discomfort, evolution of ECG abnormalities consistent with myocardial infarction, and serological evidence of myocardial necrosis. For most cohorts, stroke was diagnosed as a persistent central neurological deficit(s) lasting 24 hours and unexplained by other causes, as adjudicated by trained physician adjudicators using standard criteria In the Kaiser Permanente Study, 15 incident stroke events were ascertained from hospitalization discharge codes. For this cohort, we counted only the first hospitalization for which stroke (ICD-8 and ICD-9 codes and ICD-10 codes I60-I69) was the first-listed discharge diagnosis. Statistical Analyses LTR was calculated by a modified technique of survival analyses in which participants contribute information on the incidences of CVD, CHD, and stroke for each age they attain during follow-up. This approach has been used in numerous prior studies of LTR Each subject in the study was followed up from study entry until the occurrence of a first CVD event, death, or age 95. Remaining LTR estimates for CVD, CHD, and stroke were stratified by BP level and were calculated separately for black and white men and women beginning at 45, 55, 65, and 75 years of age. LTR estimates for CVD, CHD, and stroke were also stratified by change in BP category for the index age of 55 years. Because of the limited number of blacks and overall similar patterns of association with BP, blacks and whites were combined in estimates of LTR by change in
3 Allen et al Changes in Blood Pressure and Lifetime Risk for CVD 39 Table 1. The 10-, 20-, 30-, and 40- Year Cumulative Risks for Cardiovascular Disease Adjusted for Competing Risk Starting at the Index Age of 55 Years by Sex and Race Cumulative Adjusted Risk (95% Confidence Interval) Specified Follow-Up Starting at Index Age of 55 y Men Women Whites Normal blood 8.7 ( ) 21.3 ( ) 39.8 ( ) ( ) 9.2 ( ) 27.8 ( ) 46.1 ( ) Pre 9.6 ( ) 27.7 ( ) 50.8 ( ) 61.8 ( ) 3.3 ( ) 13.9 ( ) 38.1 ( ) 56.2 ( ) Stage ( ) 32.7 ( ) 57.1 ( ) ( ) 19.6 ( ) 45.9 ( ) 64.7 ( ) Stage ( ) 38.8 ( ) 59.3 ( ) ( ) 30.5 ( ) 53.7 ( )... Blacks Normal blood 11.7 ( ) 23.5 ( ) ( ) 19.0 ( ) Pre 14.3 ( ) 29.9 ( ) 49.3 ( ) ( ) 15.2 ( ) 35.3 ( )... Stage ( ) 38.4 ( ) 53.3 ( ) ( ) 34.8 ( ) Stage ( ) 41.2 ( ) ( ) 37.1 ( ) Indicates limited person-years of follow-up, precluding a stable estimate. BP. LTRs to 85 years of age by strata of change in BP were estimated. Given the uncertainty associated with small numbers, LTR estimates are reported only when the adjusted person-time exceeded 100 person-years at the extremes of age. All statistical analyses were performed with SAS statistical software version 9.1 (SAS Institute, Inc, Cary, NC). Results Study Sample and Remaining LTR for CVD, CHD, and Stroke A total of men and women were followed up from 55 years of age and contributed person-years of followup. The numbers of participants, events, and person-years of follow-up for stroke, CHD, and CVD at the index ages of 45, 55, 65, and 75 years are shown in Table II in the online-only Data Supplement. Given the large number of participants and years of follow-up at the index age of 55 years and the relatively few events that occurred before this age, we focused our findings on the remaining LTR starting at the index age of 55 years. Overall, starting at the age of 55 years, the remaining LTR for CVD was 52.5% (95% confidence interval [CI], ) for men and 39.9% (95% CI, ) for women, for CHD was 30.9% (95% CI, ) for men and 17.5% (95% CI, ) for women, and for stroke was 11.2% (95% CI, ) for men and 14.7% (95% CI, ) for women. Remaining LTR by BP at Index Age When participants were categorized according to their BP at the index age of 55 years, 25.7% of men and 40.8% of women had normal BPs, 49.4% of men and 47.5% of women had pre, 18.1% of men and 9.6% of women had stage 1, and 6.8% of men and 2.2% of women had stage 2 or treated. The LTR for CVD, CHD, and stroke increased with increasing BP category for both men and women (Tables 1 3, the Figure, and Table IV in the online-only Data Supplement). LTR for CVD by BP was similar for the index age of 45 years (Figure I in the online-only Data Supplement). As shown in Table 4, the higher the BP level was, the younger the age was at which participants reached a LTR for CVD, CHD, and stroke of 8% (a measure of early burden and approximately half of the remaining LTR to 85 years of age). In general, black women had the greatest age difference (9 21 years) between when the lowest and highest BP strata reached an LTR of 8%; the difference was largest for stroke. The age at which blacks reached a higher LTR was younger than for whites at almost all BP levels. These patterns were similar when cohorts were examined individually and when results were examined with and without the relatively large number of WHI participants (Table IV in the online-only Data Supplement). BP Changes During Middle Age More than half of all men and women remained in consistent BP strata from 41 through 55 years of age (Table III in the online-only Data Supplement). Almost 20% of men experienced decreases in their BP and 30% experienced increases before 55 years of age. In contrast, almost 40% of women experienced an increase in BP and only 10% experienced a decrease before 55 years of age. At baseline, men tended to have higher systolic BPs; however, by the index age of 55 years, systolic BPs were higher among women owing to larger increases in BP observed among women during middle age. Individuals who became hypertensive during middle age experienced the largest increases in systolic BP with an increase of 32 mm Hg. Women had lower diastolic BPs in all categories. Changes in diastolic BP over middle age were similar for both men and women. Participants who experienced decreases in BP during middle age had smaller increases in total cholesterol and body mass index compared with participants who maintained their BP or experienced increasing BP.
4 40 Circulation January 3/10, 2012 Table 2. The 10-, 20-, 30-, and 40-Year Cumulative Risks for Coronary Heart Disease Adjusted for Competing Risk Starting at the Index Age of 55 Years by Sex and Race Cumulative Adjusted Risk (95% Confidence Interval) Specified Follow-Up Starting at Index Age of 55 y Men Women Whites Normal blood 5.9 ( ) 13.6 ( ) 22.9 ( ) 29.0 ( ) 1.1 ( ) 4.3 ( ) 11.0 ( ) 18.3 ( ) Pre 7.0 ( ) 18.0 ( ) 30.1 ( ) 35.4 ( ) 1.7 ( ) 6.8 ( ) 16.3 ( ) 23.4 ( ) Stage ( ) 21.2 ( ) 34.8 ( ) 39.6 ( ) 2.7 ( ) 9.7 ( ) 22.1 ( ) 28.8 ( ) Stage ( ) 25.4 ( ) 37.5 ( ) ( ) 14.7 ( ) 26.6 ( )... Blacks Normal blood 5.9 ( ) 10.9 ( ) ( ) 4.8 ( ) Pre 6.7 ( ) 13.0 ( ) 25.7 ( ) ( ) 4.9 ( ) 14.8 ( )... Stage ( ) 17.3 ( ) 25.4 ( ) ( ) 12.2 ( ) Stage ( ) 18.0 ( ) ( ) 13.3 ( ) Indicates limited person-years of follow-up, precluding a stable estimate. Change in BP and Remaining LTR for Stroke Men and women who consistently had BPs 120/ 80 mm Hg and those whose BP decreased to 120/ 80 mm Hg over time tended to have the lowest remaining LTR for CVD, CHD, and stroke (Table 5). The remaining LTRs were similar for individuals whose BP was consistently 120/ 80 mm Hg and those whose BP decreased to this level. Individuals whose BP increased over time before 55 years of age had higher LTRs compared with those whose BP remained stable or decreased before 55 years of age. Although the findings were similar for men and women, men who had throughout middle life experienced the highest remaining LTR for stroke, whereas men whose BP increased to hypertensive levels had the highest LTRs for CVD and CHD. In contrast, women whose BP increased to hypertensive levels by 55 years of age had the highest LTR for stroke, but those who consistently had hypertensive levels before 55 years of age had the highest LTRs for CVD and CHD. Discussion Among the cohorts included in the Lifetime Risk Pooling Project, the remaining LTR for CVD was 52.5% in men and Table 3. The 10-, 20-, 30-, and 40-Year Cumulative Risks for Stroke Adjusted for Competing Risk Starting at the Index Age of 55 Years by Sex and Race Cumulative Adjusted Risk (95% Confidence Interval) Specified Follow-Up Starting at Index Age of 55 y Men Women Whites Normal blood 1.2 ( ) 3.4 ( ) 7.7 ( ) 10.8 ( ) 0.5 ( ) 2.4 ( ) 7.3 ( ) 12.8 ( ) Pre 1.7 ( ) 5.3 ( ) 9.7 ( ) 11.4 ( ) 0.8 ( ) 3.1 ( ) 8.3 ( ) 14.1 ( ) Stage ( ) 5.4 ( ) 9.6 ( ) 11.5 ( ) 1.7 ( ) 5.5 ( ) 11.1 ( ) 16.7 ( ) Stage ( ) 6.8 ( ) 9.1 ( ) ( ) 9.9 ( ) 15.8 ( )... Blacks Normal blood 3.7 ( ) ( ) 7.7 ( ) Pre 5.8 ( ) 8.2 ( ) 8.2 ( ) ( ) 4.5 ( ) 9.0 ( )... Stage ( ) 13.8 ( ) 15.0 ( ) ( ) 7.3 ( ) Stage ( ) 12.1 ( ) ( ) 13.2 ( ) Indicates limited person-years of follow-up, precluding a stable estimate.
5 Allen et al Changes in Blood Pressure and Lifetime Risk for CVD 41 Figure. Cumulative lifetime risk (percent) of cardiovascular disease (CVD), coronary heart disease (CHD), and stroke adjusted for competing risk of non-cvd death by blood (BP) category for men (A) and women (B). 39.9% in women. The LTR for CVD was higher among blacks compared with whites of the same sex and increased with increasing BP at the index age. Changes in BP during middle age appear to have a substantial impact on the LTR for stroke. Almost 70% of all men who develop in middle age will experience a CVD event by 85 years of age. Among women, those who have from 41 through 55 years of age have the greatest LTR for CVD at 49.4%. Individuals who are able to maintain a normal BP or to decrease their BP to normal levels during middle age have Table 4. Age at Which Cumulative Lifetime Risk for Cardiovascular Disease, Coronary Heart Disease, and Stroke Exceeds 8% by Blood Pressure Category at the Index Age of 55 Years Blood Pressure Category Normal Pre Stage 1 Hypertension Stage 2 Hypertension Cardiovascular disease 8% lifetime risk, y White men Black men White women Black women Coronary heart disease 8% lifetime risk, y White men Black men White women Black women Stroke 8% lifetime risk, y White men Black men White women Black women Indicates limited person-years of follow-up, precluding a stable estimate.
6 42 Circulation January 3/10, 2012 Table 5. Cumulative Lifetime Risk for Fatal/Nonfatal Stroke, Coronary Heart Disease, and Cardiovascular Disease by Blood Pressure Categories at Baseline and Index Ages BP Category at Baseline ( 10 y Before Remaining Lifetime Risk (95% CI) 85 Years of Age Index Age) BP Category at Index Age, mm Hg Stroke CHD CVD Men 120/ / ( ) 24.8 ( ) 41.0 ( ) / ( ) 33.6 ( ) 52.2 ( ) 140/ 90/Rx 23.5 ( ) 30.5 ( ) 69.0 ( ) / / ( ) 24.6 ( ) 34.5 ( ) / ( ) 34.7 ( ) 50.7 ( ) 140/ 90/Rx 19.2 ( ) 45.0 ( ) 65.3 ( ) 140/ 90/Rx 120/ / ( ) 32.3 ( ) 59.4 ( ) 140/ 90/Rx 23.6 ( ) 43.3 ( ) 65.3 ( ) Women 120/ / ( ) 5.8 ( ) 21.8 ( ) / ( ) 14.6 ( ) 34.1 ( ) 140/ 90/Rx 26.0 ( ) 13.5 ( ) 42.2 ( ) / / ( ) 12.2 ( ) 24.7 ( ) / ( ) 16.6 ( ) 38.9 ( ) 140/ 90/Rx 22.4 ( ) 21.7 ( ) 47.2 ( ) 140/ 90/Rx 120/ / ( ) 15.8 ( ) 36.5 ( ) 140/ 90/Rx 19.4 ( ) 24.9 ( ) 49.4 ( ) BP indicates blood ; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular disease; Rx; treatment; and..., limited person-years of follow-up, precluding a stable estimate. significantly lower LTRs for CVD, 35% to 40% and 22% to 25% for men and women, respectively. Among the white participants of the FHS (40 59 years of age), previous estimates for the LTR of CVD, 51.7% for men and 39.2% for women, were similar to those in this study, 52.5% and 39.9%, respectively. 25 LTR estimates for CHD were lower in this study compared with previous estimates from the FHS, 30.9% versus 40.8% for men and 17.5% versus 24.6% in women. 5 Similarly, LTR estimates for stroke were slightly lower in this study compared with previous estimates from the FHS, 11.2% versus 14.5% for men and 14.7% versus 18.1% in women, although participants in the FHS were followed up to 106 years of age compared with 95 years of age in this study. 8 Birth-cohort effects may explain the lower LTRs for stroke observed in this study because FHS participants were recruited into the original FHS cohort in 1948 compared with some of the more contemporary cohorts included in the Lifetime Risk Pooling Project. Significant declines in BP levels have occurred over the past 50 years as a result of improvements in population levels of untreated BP and increased treatment and control of Even within the FHS, Carandang et al 29 found a trend toward decreased LTR of stroke from 1950 to Although decreasing population BP levels may have resulted in slightly lower overall LTR estimates than those previously published by the FHS, analyses within the Lifetime Risk Pooling Project have demonstrated that, regardless of changes in prevalence, the association between BP and LTR for CVD remains the same over time within strata. 7 Prior estimates for the LTR for CVD have been based on single BP measurements taken at or near the index age. However, individuals are exposed to different BP levels throughout their life; thus, a more detailed examination of the effect of BP exposure is warranted. Systolic BP tends to increase linearly throughout middle age, although there is variability in the slope of the increase. 9 Individuals with the highest levels of systolic BP at baseline appear to have the largest age-related linear increases in systolic BP. 9 Above and beyond current BP, antecedent BP has been found to be an important determinant in risk for CVD. 30 Specifically examining stroke risk, studies done among Japanese populations have found that, in addition to current BP, BP increases over the prior 20 years represent an independent risk factor for stroke. 31 Individuals who were found to have at multiple time points had the greatest risk for stroke. 32 The present study is the first to examine how changes in BP throughout middle age (average change from 41 to 55 years of age) affect subsequent LTRs for CVD, CHD, and stroke among a large, diverse US population. We found that individuals who maintained or reduced their BP to normal levels by 55 years of age had the lowest LTRs. Decreases in BP may have been due to lifestyle changes, as suggested by the changes in body mass index and total cholesterol, although it is possible that differences were due to random variation or regression to the mean. The highest LTR for CVD among men was among those who developed during middle age. In contrast, among women, individuals who had from 41 through 55 years of age had the highest LTR for CVD. Although it was not consistently evident that a longer
7 Allen et al Changes in Blood Pressure and Lifetime Risk for CVD 43 duration of high BP was associated with increased LTRs, it is possible that a greater duration of is associated with increased competing risk from non-cvd mortality. Our findings suggest the hypothesis that there may be a dose-response effect for the length of time at higher BPs. Buck et al 33 found that the cardiovascular risk for hypertensive patients was highest for those who developed at younger ages and declined as age of onset increased from 40 to 69 years of age. Similarly, patterns in our findings suggest that women who had developed by early middle age (mean age, 41 years) had a higher LTR for CVD and CHD compared with those who had developed later in middle age, at 55 years of age. A similar pattern was seen among men when examining the remaining LTR of stroke. This study has several strengths. First, we examined the LTR for CVD among a large, diverse sample of populationbased cohorts. These analyses included almost person-years of follow-up. Many of the cohorts included in the Lifetime Risk Pooling Project are more contemporary than those used to derive prior estimates of the LTR for stroke, thereby providing more current LTR estimates. Importantly longitudinal BP measurements were available, allowing us to examine how BP changes over an average of 14 years during middle age affect the LTR for CVD. However, some individuals may not have had a second BP available because of death or, more likely, the cohort structure and timing of visits. These individuals therefore would not have been included in our analyses of BP change. Despite pooling, there was limited follow-up for blacks; therefore, we had to combine races in our analyses on change in BP and were unable to determine racial differences in the association between BP changes and LTR for CVD. By examining stratified estimates, we have adjusted for any confounding by age, race, sex, and BP; however, the methods used to determine LTR do not allow for adjustment, so there may be potential confounding by other factors such as socioeconomic status, body mass index, and other behavioral factors that could not be included in the model. In addition, we pooled multiple population-based cohorts, and there is a potential for heterogeneity resulting from birth-cohort effects and/or secular trends in the LTR estimates. Although there have been secular trends in the CVD event rates and treatment patterns, 29 most of the follow-up we have is before the widespread use of antihypertensives and lipid-lowering therapies. In the Lifetime Risk Pooling Project, the prevalence of risk factors has changed over birth cohorts; however, the relationships between risk factors and outcomes have remained remarkably consistent across cohorts and birth cohorts in the Lifetime Risk Pooling Project. In addition, changes in an individual s treatment status during follow-up may have affected that person s remaining LTR for CVD. However, the data we used to estimate LTRs for stroke are similar to what would be available to patients and clinicians at a given index age, without knowledge of subsequent changes in treatment strategy. Given the limited follow-up duration, it is not possible to estimate LTRs using only data from cohorts recruited in the last decade, when antihypertensive use has become prevalent. Our results suggest that there may be a dose-response effect for the number of years with high BP on the LTR of CVD, CHD, and stroke. Individuals who are able to maintain or to decrease their BP to normal BP levels during middle age have the lowest LTR for CVD. In contrast, individuals who experience an increase in BP have higher LTRs for CVD. Taking BP changes into account can provide more accurate estimates for LTR for CVD and represent a step forward in developing individualized risk prediction strategies. Therefore, avoiding before middle age and delaying the onset of the development of both appear to have a significant impact on an individual s remaining LTR for CVD. Acknowledgments The investigators of the Cardiovascular Lifetime Risk Pooling Project wish to extend their deepest gratitude to the investigators of all of the included cohort studies for their hard work and dedication in collecting the underlying data and especially to the participants in the cohorts, whose dedication and commitment have formed the basis of profound observations on health and disease that have contributed to improved health, longevity, and quality of life for millions of individuals. Sources of Funding Dr Lloyd-Jones had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr Lloyd-Jones and this work are supported in part by grant R21 HL from the NHLBI. As part of his research training, Dr Allen has received support from a Ruth Kirschstein NRSA/NHLBI fellowship at Northwestern University Feinberg School of Medicine (T32 HL ). The ARIC Study, FHS, FOS, and HHP are conducted and supported by the NHLBI in collaboration with the study investigators. This manuscript was prepared using limited-access data sets obtained from the NHLBI for these studies and does not necessarily reflect the opinions or views of the study investigators or the NHLBI. The research reported in this article from the CHS was supported by contracts N01-HC through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, and N01-HC and grant U01 HL from the NHLBI, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at The WHI program is funded by the NHLBI, National Institutes of Health, US Department of Health and Human Services through contracts N01WH22110, 24152, , , , , 32115, , 32122, , , and We thank the WHI investigators and staff for their dedication and the study participants for making the program possible. A full listing of WHI investigators can be found at None. Disclosures References 1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics 2011 update: a report from the American Heart Association. Circulation. 2011;123: e18 e Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Petitti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC Jr, Sopko G, Steinhorn RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK. Evidence-based guidelines for cardiovas-
8 44 Circulation January 3/10, 2012 cular disease prevention in women: 2007 update. Circulation. 2007; 115: Wilkins J, Lloyd-Jones D. Short-term versus lifetime risk assessment for cardiovascular disease: pros, cons, and clinical implications. Curr Cardiovasc Risk Rep. 2009;3: Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham study. Lancet Neurol. 2007;6: Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353: Lloyd-Jones DM, Dyer AR, Wang R, Daviglus ML, Greenland P. Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry). Am J Cardiol. 2007;99: Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Horn LV, Tracy RP, Lloyd-Jones DM. Lifetime risks for cardiovascular disease by age and risk factor burden. N Engl J Med. In Press. 8. Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, Wolf PA. The lifetime risk of stroke: estimates from the Framingham study. Stroke. 2006;37: Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood : the Framingham Heart Study. Circulation. 1997;96: ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol. 1989;129: Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham study. Ann N Y Acad Sci. 1963;107: Kannel WB, Manning F, McNamara P, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110: Kagan A, Harris BR, Winkelstein W Jr, Johnson KG, Kato H, Syme SL, Rhoads GG, Gay ML, Nichaman MZ, Hamilton HB, Tillotson J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chronic Dis. 1974;27: Worth RM, Kagan A. Ascertainment of men of Japanese ancestry in Hawaii through World War II Selective Service registration. J Chronic Dis. 1970;23: Haan MN, Selby JV, Rice DP, Quesenberry CP Jr, Schofield KA, Liu J, Fireman BH. Trends in cardiovascular disease incidence and survival in the elderly. Ann Epidemiol. 1996;6: Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1: Women s Health Initiative Study Group. Design of the Women s Health Initiative clinical trial and observational study. Control Clin Trials. 1998; 19: Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289: Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294: Yano K, Grove JS, Reed DM, Chun HM. Determinants of the prognosis after a first myocardial infarction in a migrant Japanese population: the Honolulu Heart Program. Circulation. 1993;88: Beiser A, D Agostino RB Sr, Seshadri S, Sullivan LM, Wolf PA. Computing estimates of incidence, including lifetime risk: Alzheimer s disease in the Framingham Study: the Practical Incidence Estimators (PIE) macro. Stat Med. 2000;19: Gaynor J, Feuer E, Tan C, Wu D, Little C, Straus D, Clarkson B, Brennan M. On the use of cause-specific failure and conditional failure probabilities. J Am Stat Assoc. 1993;88: Berry JD, Garside DB, Cai X, Dyer AR, Lloyd-Jones DM. Remaining lifetime risks for cardiovascular disease death by risk factor burden at selected ages in black and white men and women [abstract]. Circulation. 2007;116:II-832a. 24. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106: Lloyd-Jones DM, Leip EP, Larson MG, D Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113: Luepker RV, Arnett DK, Jacobs DR Jr, Duval SJ, Folsom AR, Armstrong C, Blackburn H. Trends in blood, control, and stroke mortality: the Minnesota Heart Survey. Am J Med. 2006;119: Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of in the United States, JAMA. 2003; 290: Kumanyika SK, Landis JR, Matthews-Cook YL, Almy SL, Boehmer SJ. Systolic blood trends in US adults between 1960 and 1980: influence of antihypertensive drug therapy. Am J Epidemiol. 1998;148: Carandang R, Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Kannel WB, Wolf PA. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA. 2006;296: Vasan RS, Massaro JM, Wilson PW, Seshadri S, Wolf PA, Levy D, D Agostino RB. Antecedent blood and risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2002;105: Shimizu Y, Kato H, Lin CH, Kodama K, Peterson AV, Prentice RL. Relationship between longitudinal changes in blood and stroke incidence. Stroke. 1984;15: Kikumura T, Omae T, Ueda K, Takeshita M, Hirota Y. Long-term changes in blood prior to the development of cerebral infarction: the Hisayama study. J Chronic Dis. 1981;34: Buck C, Baker P, Bass M, Donner A. The prognosis of according to age at onset. Hypertension. 1987;9: CLINICAL PERSPECTIVE Prior estimates of lifetime risk for cardiovascular disease (CVD) examined the impact of blood (BP) at the index age and did not account for changes in BP over time. Using pooled data from 7 diverse US cohort studies, we examined how changes in BP during middle age affect the lifetime risk for CVD, coronary heart disease, and stroke. Remaining lifetime risk from 55 years of age for CVD, coronary heart disease, and stroke was estimated for white and black men and women by BP strata and by changes in BP over an average of 14 years. Lifetime risk for CVD was 52.5% (95% confidence interval, ) for men and 39.9% (95% confidence interval, ) for women. Lifetime risk for CVD was higher for blacks and increased with increasing BP at index age. Individuals who maintained or decreased their BP to normal levels had the lowest remaining lifetime risk for CVD, 21% to 41%, compared with individuals who had or developed by 55 years of age, 49.4% to 69.0%. Individuals who experience increases or decreases in BP in middle age have associated higher and lower remaining lifetime risk for CVD, and there may be a dose-response effect for the length of time at high BP levels. Prevention efforts should continue to emphasize the importance of lowering BP and avoiding or delaying the incidence of to reduce the lifetime risk for CVD.
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular
More informationTEN-YEAR ABSOLUTE RISK ESTImates
ORIGINAL CONTRIBUTION CLINICIAN S CORNER Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Scan for Author Video Interview John T. Wilkins, MD, MS Hongyan Ning, MD, MS Jarett Berry, MD,
More informationDonald M. Lloyd-Jones, MD, ScM a,b, *, Alan R. Dyer, PhD a, Renwei Wang, MS a, Martha L. Daviglus, MD, PhD a, and Philip Greenland, MD a,b
Risk Factor Burden in Middle Age and Lifetime Risks for Cardiovascular and Non-Cardiovascular Death (Chicago Heart Association Detection Project in Industry) Donald M. Lloyd-Jones, MD, ScM a,b, *, Alan
More informationThe majority of US adults, particularly women and. Original Articles
Original Articles Distribution of 10-Year and Lifetime Predicted Risks for Cardiovascular Disease in US Adults Findings From the National Health and Nutrition Examination Survey 2003 to 2006 Amanda K.
More informationLifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart Study
Diabetes Care Publish Ahead of Print, published online May 5, 2008 Lifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart
More informationLifetime Risks of Cardiovascular Disease
original article Lifetime Risks of Cardiovascular Disease Jarett D. Berry, M.D., Alan Dyer, Ph.D., Xuan Cai, M.S., Daniel B. Garside, B.S., Hongyan Ning, M.D., Avis Thomas, M.S., Philip Greenland, M.D.,
More informationJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 64, NO. 10, 2014 ª 2014 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 64, NO. 1, 214 ª 214 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 735-197/$36. PUBLISHED BY ELSEVIER INC. http://dx.doi.org/1.116/j.jacc.214.6.1186
More informationYOUNG ADULT MEN AND MIDDLEaged
BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationSudden cardiac death (SCD) is a leading cause of death in
Lifetime Risk for Sudden Cardiac Death in the Community Brittany M. Bogle, PhD, MPH; Hongyan Ning, MD, MS; Sanjay Mehrotra, PhD; Jeffrey J. Goldberger, MD; Donald M. Lloyd-Jones, MD, ScM Background- Sudden
More informationHypertension in Adults Across the Age Spectrum
ORIGINAL CONTRIBUTION Hypertension in Adults Across the Age Spectrum Current Outcomes and Control in the Community Donald M. Lloyd-Jones, MD, ScM Jane C. Evans, DSc Daniel Levy, MD ELDERLY PERSONS ARE
More informationLifetime Risks for Cardiovascular Disease Mortality by Cardiorespiratory Fitness Levels Measured at Ages 45, 55, and 65 Years in Men
Journal of the American College of Cardiology Vol. 57, No. 15, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.056
More informationThe association between high-density lipoprotein cholesterol
Coronary Heart Disease Risks Associated with High Levels of HDL Cholesterol John T. Wilkins, MD, MS; Hongyan Ning, MD, MS; Neil J. Stone, MD; Michael H. Criqui, MD, MPH; Lihui Zhao, PhD; Philip Greenland,
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationCONSIDERABLE STRIDES HAVE
ORIGINAL INVESTIGATION Comparison of Risk Factors for Cardiovascular Mortality in Black and White Adults Mercedes R. Carnethon, PhD; Elizabeth B. Lynch, PhD; Alan R. Dyer, PhD; Donald M. Lloyd-Jones, MD,
More informationThe Whitehall II study originally comprised 10,308 (3413 women) individuals who, at
Supplementary notes on Methods The study originally comprised 10,308 (3413 women) individuals who, at recruitment in 1985/8, were London-based government employees (civil servants) aged 35 to 55 years.
More informationNovel Approach to Examining First Cardiovascular Events After Hypertension Onset
Novel Approach to Examining First Cardiovascular Events After Hypertension Onset Donald M. Lloyd-Jones, Eric P. Leip, Martin G. Larson, Ramachandran S. Vasan, Daniel Levy Abstract Hypertension confers
More informationMuch of the United States adult population is at risk of
Absolute and Attributable Risks of Heart Failure Incidence in Relation to Optimal Risk Factors Aaron R. Folsom, MD; Kazumasa Yamagishi, MD, PhD; Atsushi Hozawa, MD, PhD; Lloyd E. Chambless, PhD; for the
More informationPreventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex
Prevention and Rehabilitation Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Nathan D. Wong, PhD, a Gaurav Thakral, BS, a Stanley S. Franklin,
More informationAtrial fibrillation (AF) is the most common chronic
Lifetime Risk for Development of Atrial Fibrillation The Framingham Heart Study Donald M. Lloyd-Jones, MD, ScM; Thomas J. Wang, MD; Eric P. Leip, MS; Martin G. Larson, ScD; Daniel Levy, MD; Ramachandran
More informationAntihypertensive Drug Therapy and Survival by Treatment Status in a National Survey
1-28 Antihypertensive Drug Therapy and Survival by Treatment Status in a National Survey Richard J. Havlik, Andrea Z. LaCroix, Joel C. Kleinman, Deborah D. Ingram, Tamara Harris, and Joan Cornoni-Huntley
More informationCardiovascular diseases, including heart disease and
Trends in Myocardial Infarction Secondary Prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999 2012 Nilay S. Shah, MD, MPH; Mark D. Huffman, MD, MPH; Hongyan Ning, MD, MS; Donald
More informationORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths
ORIGINAL INVESTIGATION Effects of Prehypertension on Admissions and Deaths A Simulation Louise B. Russell, PhD; Elmira Valiyeva, PhD; Jeffrey L. Carson, MD Background: The Joint National Committee on Prevention,
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationApproximately 30% of adults in the United States have
Hypertension Guidelines Implications Implications of New Hypertension Guidelines in the United States Monica L. Bertoia, Molly E. Waring, Priya S. Gupta, Mary B. Roberts, Charles B. Eaton See Editorial
More informationLong-term Blood Pressure Variability throughout Young Adulthood and Cognitive Function in Midlife; CARDIA study
The EPI/NPAM Spring 2014 Scientific Sessions, Hilton San Francisco Union Square, San Francisco, CA Northwestern Mar. 18-21, 2014 University Feinberg School of Medicine Long-term Blood Pressure Variability
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright 2001 by the Massachusetts Medical Society VOLUME 345 N OVEMBER 1, 2001 NUMBER 18 IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE
More informationDiabetes Care 31: , 2008
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S. KHIET C. HOANG, MD HELI GHANDEHARI VICTOR
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationGlobal Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH
Diabetes Care Publish Ahead of Print, published online April 1, 2008 Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic Syndrome Khiet C. Hoang MD, Heli Ghandehari, BS, Victor
More informationBlood pressure (BP) is an established major risk factor for
Pulse Pressure Compared With Other Blood Pressure Indexes in the Prediction of 25-Year Cardiovascular and All-Cause Mortality Rates The Chicago Heart Association Detection Project in Industry Study Katsuyuki
More informationATRIAL FIBRILLATION AND ETHNICITY. Elsayed Z Soliman MD, MSc, MS Director, Epidemiological Cardiology Research Center (EPICARE)
ATRIAL FIBRILLATION AND ETHNICITY Elsayed Z Soliman MD, MSc, MS Director, Epidemiological Cardiology Research Center (EPICARE) Atrial fibrillation (AF) and ethnicity The known The unknown The paradox Why
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationAnalyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins. Peter Thorne
Abstract Analyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins Peter Thorne A sample of adults participating in the first 7 months of visit 5 of the Atherosclerosis
More informationEffects of Paroxetine on Mortality and Hospital Admissions in Heart Failure Patients
Effects of Paroxetine on Mortality and Hospital Admissions in Heart Failure Patients MARIE ANN NGAN, PHARM.D. OKLAHOMA CITY VA HEALTH CARE SYSTEMS PGY1 PHARMACY RESIDENT APRIL 8, 2016 Disclosure Statement
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationNIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2014 August ; 174(8): 1397 1400. doi:10.1001/jamainternmed.2014.2492. Prevalence and Characteristics of Systolic
More informationTouyz, R. M., and Dominiczak, A. F. (2016) Hypertension guidelines: is it time to reappraise blood pressure thresholds and targets? Hypertension, 67(4), pp. 688-689. There may be differences between this
More informationThe purpose of this report is to compare the results of
Comparison of Two Measures of Atherosclerosis in a Prospective Epidemiology Study Dwayne M. Reed, Jack P. Strong, Takuji Hayashi, W. P. ewman III, Richard E. Tracy, Miguel A. Guzman, and Grant. Stemmermann
More informationThe recently released American College of Cardiology
Data Report Atherosclerotic Cardiovascular Disease Prevention A Comparison Between the Third Adult Treatment Panel and the New 2013 Treatment of Blood Cholesterol Guidelines Andre R.M. Paixao, MD; Colby
More informationPsychosocial Factors Are Associated With Blood Pressure Progression Among African Americans in the Jackson Heart Study
Original Article Psychosocial Factors Are Associated With Blood Pressure Progression Among African Americans in the Jackson Heart Study Cassandra D. Ford, 1 Mario Sims, 2 John C. Higginbotham, 3 Martha
More informationElevated blood pressure (BP) is a major modifiable risk factor
Blood Pressure in Adulthood and Life Expectancy With Cardiovascular Disease in Men and Women Life Course Analysis Oscar H. Franco, Anna Peeters, Luc Bonneux, Chris de Laet Abstract Limited information
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationJournal of the American College of Cardiology Vol. 57, No. 16, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 57, No. 16, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.041
More informationBlood Pressure Assessment Practices of Dental Hygienists
Blood Pressure Assessment Practices of Dental Hygienists Abstract An estimated 50 million Americans have high blood pressure (HBP), with 30% of them unaware of their condition. Both the American Dental
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationCardiovascular Disease Risk of Abdominal Obesity vs. Metabolic Abnormalities
nature publishing group articles Cardiovascular Disease Risk of Abdominal Obesity vs. Metabolic Abnormalities Rachel P. Wildman 1, Aileen P. McGinn 1, Juan Lin 1, Dan Wang 1, Paul Muntner 2, Hillel W.
More informationthe U.S. population, have some form of cardiovascular disease. Each year, approximately 6 million hospitalizations
Cardioprotection: What is it? Who needs it? William B. Kannel, MD, MPH From the Department of Preventive Medicine and Epidemiology, Evans Department of Clinical Research, Boston University School of Medicine,
More informationRisk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study
EDITORIAL by Nash 1 Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA 2 Divisions of Preventive
More informationCoronary Heart Disease
Coronary Heart Disease Characteristics and Baseline Clinical Predictors of Future Fatal Versus Nonfatal Coronary Heart Disease Events in Older Adults The Cardiovascular Health Study Camille A. Pearte,
More informationPrediction of Cardiovascular Death in Racial/Ethnic Minorities Using Framingham Risk Factors
Prediction of Cardiovascular Death in Racial/Ethnic Minorities Using Framingham s Laura P. Hurley, MD, MPH; L. Miriam Dickinson, PhD; Raymond O. Estacio, MD; John F. Steiner, MD, MPH; Edward P. Havranek,
More informationPeripheral arterial disease is associated with an increased risk of atrial fibrillation in the elderly
Europace (2016) 18, 794 798 doi:10.1093/europace/euv369 CLINICAL RESEARCH Atrial fibrillation Peripheral arterial disease is associated with an increased risk of atrial fibrillation in the elderly William
More informationBuilding healthier lives, free of cardiovascular diseases
AHA Presidential Advisory The American Heart Association and the Million Hearts Initiative A Presidential Advisory From the American Heart Association Gordon F. Tomaselli, MD, FAHA; Mary-Beth Harty, MPH,
More informationNBER WORKING PAPER SERIES THE IMPACT OF ANTIHYPERTENSIVE DRUGS ON THE NUMBER AND RISK OF DEATH, STROKE AND MYOCARDIAL INFARCTION IN THE UNITED STATES
NBER WORKING PAPER SERIES THE IMPACT OF ANTIHYPERTENSIVE DRUGS ON THE NUMBER AND RISK OF DEATH, STROKE AND MYOCARDIAL INFARCTION IN THE UNITED STATES Genia Long David Cutler Ernst R. Berndt Jimmy Royer
More informationHigh Density Lipoprotein Cholesterol and Mortality
High Density Lipoprotein Cholesterol and Mortality The Framingham Heart Study Peter W.F. Wilson, Robert D. Abbott, and William P. Castelli In 12 years of follow-up for 2748 Framingham Heart Study participants
More informationUsing Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly
Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama
More informationOver the past several decades, mortality from cardiovascular
Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005 Sarah Rosner Preis, ScD, MPH; Shih-Jen Hwang,
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationHypertension awareness, treatment, and control
O r i g i n a l P a p e r Prevalence of Self-Reported High Blood Pressure Awareness, Advice Received From Health Professionals, and Actions Taken to Reduce High Blood Pressure Among US Adults Healthstyles
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationNormal systolic blood pressure and risk of heart failureinusmalephysicians
European Journal of Heart Failure (2009) 11, 1129 1134 doi:10.1093/eurjhf/hfp141 Normal systolic blood pressure and risk of heart failureinusmalephysicians Kathryn A. Britton 1,2 *, J. Michael Gaziano
More informationStroke A Journal of Cerebral Circulation
Stroke A Journal of Cerebral Circulation JULY-AUGUST VOL. 7 1976 NO. 4 Components of Blood Pressure and Risk of Atherothrombotic Brain Infarction: The Framingham Study WILLIAM B. KANNEL, M.D., THOMAS R.
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationARIC Manuscript Proposal # PC Reviewed: 05/12/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1508 PC Reviewed: 05/12/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hemostatic markers and risk of atrial fibrillation: the Atherosclerosis Risk
More informationFOR MIDDLE-AGED POPULATIONS,
ORIGINAL CONTRIBUTION Relationship of Cholesterol Levels in 3 Large Cohorts of Younger to Long-term Coronary, Cardiovascular, and All-Cause Mortality and to Longevity Jeremiah Stamler, MD Martha L. Daviglus,
More information김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과
치매예방을위한만성질환관리전략 김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과 A sharp rise in the death rate from Alzheimer s disease Ivan Casserly & Eric Topol, Lancet 2004 Potential for primary prevention of Alzheimer s disease Alzheimer
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationRelationship of Blood Pressure to Cardiovascular Death: The Effects of Pulse Pressure in the Elderly
Relationship of Blood Pressure to Cardiovascular Death: The Effects of Pulse Pressure in the Elderly MEI-LING T. LEE, PhD, BERNARD A. ROSNER, PhD, AND SCOTT T. WEISS, MD PURPOSE: To investigate the relationship
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process
More informationFolate, vitamin B 6, and vitamin B 12 are cofactors in
Research Letters Dietary Folate and Vitamin B 6 and B 12 Intake in Relation to Mortality From Cardiovascular Diseases Japan Collaborative Cohort Study Renzhe Cui, MD; Hiroyasu Iso, MD; Chigusa Date, MD;
More informationRisk Factors for Heart Disease
Developmental Perspectives on Health Disparities from Conception Through Adulthood Risk Factors for Heart Disease Philip Greenland, MD Harry W. Dingman Professor Chair, Department of Preventive Medicine
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationFour Tissue Segmentation in ADNI II
Four Tissue Segmentation in ADNI II Charles DeCarli, MD, Pauline Maillard, PhD, Evan Fletcher, PhD Department of Neurology and Center for Neuroscience, University of California at Davis Summary Table of
More informationDiabetes and Decline in Heart Disease Mortality in US Adults JAMA. 1999;281:
ORIGINAL CONTRIBUTION and Decline in Mortality in US Adults Ken Gu, PhD Catherine C. Cowie, PhD, MPH Maureen I. Harris, PhD, MPH MORTALITY FROM HEART disease has declined substantially in the United States
More informationA Needs Assessment of Hypertension in Georgia
A Needs Assessment of Hypertension in Georgia Faye Lopez Mercer University School of Medicine Marylen Rimando Mercer University School of Medicine Harshali Khapekar Mercer University School of Medicine
More informationCardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S.
Cardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S. Item Type Thesis Authors Couch, Christopher Rights Copyright is held by the author.
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationUsing Administrative Databases to Calculate Framingham Scores Within a Large Health Care Organization
Using Administrative Databases to Calculate Framingham Scores Within a Large Health Care Organization Olaniyi James Ekundayo, MD, DrPH; Stefanie D. Vassar, MS; Linda S. Williams, MD; Dawn M. Bravata, MD;
More informationEffect of Medicine Adherence on the Occurrence of Cerebrovascular Disorders in Diabetes Mellitus Patients
Epidemiology and Health Epidemiology and Health Volume: 33, Article ID: e2011001, 6 pages DOI 10.4178/epih/e2011001 ORIGINAL ARTICLE Effect of Medicine Adherence on the Occurrence of Cerebrovascular Disorders
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationUtility of Normal Findings on Electrocardiogram and Echocardiogram in Subjects 65 Years
Utility of Normal Findings on Electrocardiogram and Echocardiogram in Subjects 65 Years Sanjay Venkatesh, Wake Forest University Wesley T. O'Neal, Emory University Stephen T. Broughton, Wake Forest University
More informationEffect of Cardiac Rehabilitation Program on Heart Rate Recovery in Coronary Heart Disease
The Journal of Tehran University Heart Center Original Article Effect of Cardiac Rehabilitation Program on Heart Rate Recovery in Coronary Heart Disease Leila Mahdavi Anari, MD 1, Mahdieh Ghanbari-Firoozabadi,
More informationASSESSING STROKE AND BLEEDING RISK
ASSESSING STROKE AND BLEEDING RISK IN ATRIAL FIBRILLATION Consensus Statement on Appropriate Anticoagulant Use EXECUTIVE SUMMARY ASSESSING STROKE AND BLEEDING RISK IN ATRIAL FIBRILLATION: Consensus Statement
More informationAchieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care
Achieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care Purpose Explore the adherence rates to cholesterol treatment targets among patients who seek care
More informationORIGINAL INVESTIGATION. Fasting and 2-Hour Postchallenge Serum Glucose Measures and Risk of Incident Cardiovascular Events in the Elderly
Fasting and 2-Hour Postchallenge Serum Glucose Measures and Risk of Incident Cardiovascular Events in the Elderly The Cardiovascular Health Study ORIGINAL INVESTIGATION Nicholas L. Smith, PhD, MPH; Joshua
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationExercise Physiology. Exercise Blood Pressure and Future Cardiovascular Death in Asymptomatic Individuals
Exercise Physiology Exercise Blood Pressure and Future Cardiovascular Death in Asymptomatic Individuals Sandra A. Weiss, MD; Roger S. Blumenthal, MD; A. Richey Sharrett, MD, DrPH; Rita F. Redberg, MD,
More informationEssential Hypertension Management Considerations By Elaine Lewis, ND
Essential Hypertension Management Considerations By Elaine Lewis, ND Elaine Lewis, ND Research Resident, Canadian College of Naturopathic Medicine 1255 Sheppard Avenue East North York, Ontario Back To
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationEpidemiology and Prevention
Epidemiology and Prevention Twenty-Two Year Trends in Incidence of Myocardial Infarction, Coronary Heart Disease Mortality, and Case Fatality in 4 US Communities, 1987 2008 Wayne D. Rosamond, PhD, MS;
More informationORIGINAL INVESTIGATION. Calcium Antagonists and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study
ORIGINAL INVESTIGATION s and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study Vivian M. Abascal, MD; Martin G. Larson, ScD; Jane C. Evans, MPH; Ana T. Blohm, BA; Kim Poli,
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationJournal of the American College of Cardiology Vol. 41, No. 6, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(03)00052-4
More informationEarly-Adulthood Cardiovascular Disease Risk Factor Profiles Among Individuals With and Without Diabetes in the Framingham Heart Study
Early-Adulthood Cardiovascular Disease Risk Factor Profiles Among Individuals With and Without Diabetes in the Framingham Heart Study The Harvard community has made this article openly available. Please
More informationHeart Disease and Stroke Statistics 2018 At-a-Glance
Heart Disease and Stroke Statistics 2018 At-a-Glance Here are a few key statistics about heart disease, stroke, other cardiovascular diseases and their risk factors, in addition to commonly cited statistics
More informationTarget Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD
Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author Waleed M. Sweileh, PhD
More information